Rotar Z, et al. - In order to investigate the risk of tuberculosis (TB) in patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS) and psoriatic arthritis (PsA) treated with any of the commercially available tumour necrosis factor inhibitors in Slovenia, researchers conducted a cohort study recruiting a total of 2,429 individuals with RA, AS or PsA exposed to at least one TNFi at all Slovenian rheumatology centres (six secondary and two secondary/tertiary). The primary endpoint measures included age-adjusted and gender-adjusted TB incidence rates (IRs) and the standardised incidence ratios compared with the general population exploring different TNFi exposure windows. A detailed characterisation of the national latent tuberculosis infection screening and TB chemoprophylaxis protocol implementation were considered as secondary endpoint measures. The results of this study indicated that the TB IR in the Slovenian individuals with RA, AS and PsA treated with TNFi was comparable with TB IRs in TB non-endemic countries with less than a tenth of the individuals needing TB chemoprophylaxis.